Search Follow us

EdisonTV

NeuroVive Pharmaceutical

EdisonTV | Pharmaceuticals & healthcare | 24/04/2018

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.

Read the report

Bitesize Briefing - Cannabis sector report

Bitesize Briefing - Cannabis sector report

In this video, Maxim Jacobs discusses key findings from his recently published sector report on Cannabis.
Watch »

16/05/2019 |

Executive Interview - VolitionRx

Executive Interview - VolitionRx

In this video, the company’s chief executive officer, Cameron Reynolds, discusses the latest newsflow, highlights from the capital markets day in New York and what comes next for VolitionRx.
Watch »

24/04/2019 | VolitionRx

Bitesize briefing – clinical trials, outcomes and endpoints

Bitesize briefing – clinical trials, outcomes and endpoints

In this briefing Sabah Meddings of the Sunday Times and healthcare analyst Andy Smith discuss his recent note, Trial outcomes and value – explaining contemporary clinical trial issues. They discuss how the detail of pharmaceutical and biotechnology company clinical trials is relevant to investors. They also touch on the debate surrounding the confidentiality of interactions between drug sponsors and regulators and whether this is material to investors.
Watch »

17/04/2019 |

Executive interview - Herantis

Executive interview - Herantis

Herantis Pharma was created by a merger of two Finnish pharmaceutical companies, Hermo Pharma and Laurantis Pharma. Its research is a result of scientific discoveries made by Professor Mart Saarma and Professor Kari Alitalo at the University of Helsinki. Herantis listed on NASDAQ OMX Helsinki First North Finland in 2014. In this video, CEO Pekka Simula introduces the company and its assets, including its CDNF asset which is under clinical investigation for Parkinson’s disease and utilises the same drug-delivery device highlighted in a recent BBC documentary on GDNF.
Watch »

15/04/2019 |

Executive interview - CytoDyn

Executive interview - CytoDyn

CytoDyn is on the cusp of potentially garnering its first FDA approval for its lead drug, Leronlimab (PRO 140) in HIV. In this video, the CEO and chief medical officer discuss how the company reached this point and what’s next, including a potentially transformative pipeline of opportunities in metastatic cancer, also now in development.
Watch »

15/04/2019 |

Executive interview - Selvita

Executive interview - Selvita

In this video, the company’s chief executive officer Paweł Przewięźlikowski introduces the company and lead assets, and provides an overview of R&D progress and expected news flow.
Watch »

12/04/2019 | Selvita

Executive interview - Shield Therapeutics

Executive interview - Shield Therapeutics

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom that listed on AIM in 2016. Its primary focus is the commercialisation of Feraccru, approved by the EMA for the treatment of iron deficiency, with or without anaemia. Commercialisation of Feraccru in key markets (ex US) is in the hands of distribution partners Norgine, AOP Orphan and Ewopharma. In this video, the company’s CEO and co-founder Carl Sterritt introduces the company and Feraccru, discusses the recently announced positive top-line data from a Phase IIIb marketing study (AEGIS-H2H) and the commercialisation strategy for Feraccru in the US once a decision on regulatory approval is reached by the US FDA (PDUFA date of 27 July 2019).
Watch »

25/03/2019 | Shield Therapeutics

Executive interview - Actinogen Medical

Executive interview - Actinogen Medical

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. Primary indication is cognitive impairment in mild AD patients and results from the ongoing Phase II XanADu trial are expected to be announced in Q219. In this video, the company’s chief executive officer Bill Ketelbey introduces the company and lead asset, and provides an overview of R&D progress and expected news flow.
Watch »

21/03/2019 | Actinogen Medical

Executive interview - VolitionRx Discusses FY18 Results and Provides a Business Update

Executive interview - VolitionRx Discusses FY18 Results and Provides a Business Update

In this interview, Cameron Reynolds, President and Chief Executive Office of Volition, discusses the Company’s financial results and provides a business update for the full fiscal year ended December 31, 2018. The Company made significant progress on building out it’s Nu.QTM platform and reported positive initial data from its first product grade assays. The team aims to further strengthen their product pipeline beyond colorectal cancer to include several cancers and diseases, along with advancing the Nu.Q Capture and Nu.Q Vet products to help drive early revenue.
Watch »

15/03/2019 | VolitionRx

Bitesize briefing - drug pricing

Bitesize briefing - drug pricing

The Sunday Times pharmaceuticals correspondent Sabah Meddings and Edison's healthcare Analyst Andy Smith discuss some of the issues, causes and effects of increasing drug prices reviewed in Edison's recent note on drug pricing, reimbursement and market access.
Watch »

08/03/2019 |

Executive interview – ROVI

Executive interview – ROVI

Laboratorios Farmacéuticos ROVI is a fully integrated, profitable Spanish pharmaceutical company established in 1946 which listed on the Madrid Stock Exchange in 2007. ROVI is involved in the research and development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs. ROVI has a particular expertise in low molecular weight heparins (LMWH), with internally developed assets Hibor (bemiparin) and Becat (enoxaparin biosimilar) being key drivers of near-term revenue and profit growth. Sustainable long-term growth is dependent on successful R&D investment and ROVI’s efforts here lie in its ISM (in situ microimplants) technology. In this video, the company’s vice president & chief financial officer Javier López-Belmonte introduces the company, its LMWH franchise and an overview the commercialisation strategy for with its Phase III asset DORIA (Risperidone ISM).
Watch »

06/03/2019 | Laboratorios Farmacéuticos ROVI

Executive interview – Cantargia

Executive interview – Cantargia

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing antibodies against target IL1RAP to treat cancer and autoimmune diseases. Lead antibody CAN04 is currently being studied in a Phase I/II study in solid tumours focusing on NSCLC and pancreatic cancer. In this video, the company’s chief executive officer Göran Forsberg introduces the company and its lead asset, and provides an overview of R&D progress and expected newsflow.
Watch »

28/02/2019 | Cantargia

Bitesize briefing - Orexo

Bitesize briefing - Orexo

In this briefing, we look back on an eventful 2018 for Orexo and forward to what’s in store for the company in 2019. We also discuss our recent note, where we examine the treatment journey of the opioid use disorder patient, and explore its commercial relevance for Orexo’s franchise.
Watch »

12/02/2019 | Orexo

Executive interview - Immunicum

Executive interview - Immunicum

Immunicum is a clinical-stage immuno-oncology company based in Stockholm, Sweden. The company is developing an allogeneic off-the-shelf dendritic cell immune activator (immune primer) for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in various solid tumour indications. In this video, the company’s chief executive officer Carlos de Sousa explains the recent R&D progress and expected newsflow.
Watch »

11/02/2019 | Immunicum

Executive interview – Verona Pharma

Executive interview – Verona Pharma

Verona Pharma’s chairman, Dr David Ebsworth, provides an overview of the group’s core technology and applications, corporate strategy and development plans for its lead product, RPL554. He also outlines expected near-term news flow and the regulatory strategy.
Watch »

10/12/2018 | Verona Pharma

Executive interview – Paion

Executive interview – Paion

CEO Dr Wolfgang Söhngen provides an overview of Paion’s core technology, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic. He also discusses the group’s strategy including partnership deals with Cosmo and Mundipharma and the path to market for Paion’s products.
Watch »

10/12/2018 | Paion

Executive interview – Ergomed

Executive interview – Ergomed

CEO Stephen Stamp discusses trends in the pharmacovigilance and clinical research markets as well as the current structure and focus of the business following the acquisition of PSR.
Watch »

10/12/2018 | Ergomed

Executive interview – InflaRx

Executive interview – InflaRx

CEO and founder, Niels Riedemann, discusses InflaRx’s core technology including its lead product, IFX-1. He also highlights the advantages of the company’s acute and chronic inflammation products versus the current standard of care and the competition. Finally, he provides an update on InflaRx’s expected near-term news flow.
Watch »

10/12/2018 | InflaRx

Executive interview – PBKM

Executive interview – PBKM

Jakub Baran, CEO of PBKM, a Polish stem cell bank, discusses the group’s corporate strategy including the acquisitions made to increase its geographical reach. He also provides an overview of both the services and preclinical sides of the business.
Watch »

10/12/2018 | Expedeon

Executive Interview - Expedeon

Executive Interview - Expedeon

Dr Heikki Lanckriet, CEO of Expedeon, outlines the group’s Grow, Buy and Build strategy including recent acquisitions and the group’s acquisition criteria. He also discusses Expedeon’s financial turnaround and the impact it has made on financing recent acquisitions, before outlining the group’s five core technologies.
Watch »

06/12/2018 | Expedeon

Executive Interview - Heidelberg Pharma

Executive Interview - Heidelberg Pharma

Dr Jan Schmidt-Brand, CEO and CFO of Heidelberg discusses the group’s core technology and applications. In particular, he focuses on Heidelberg's lead product HDP-101’s route to market and its advantages over the current standard of care and competitors such as CAR-T and ADCs.
Watch »

06/12/2018 | Heidelberg Pharma